Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat in Polycythaemia Vera and Essential Thrombocythaemia
NCT00866762Phase 2Unknown
- Sponsor
- Rigshospitalet
- Start
- Feb 2009
- Primary completion
- Aug 2012
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of vorinostat in polycythemia vera (PV) and essential thrombocythemia (ET), sponsored by Rigshospitalet. Primary endpoint: Efficacy of MK-0683 at 1 year. Status: unknown.
02
Drugs
vorinostat
03
Conditions
polycythemia vera (PV)essential thrombocythemia (ET)
Beyond the preview
Go deeper on NCT00866762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00866762.